CRISPR: No Sign of Slowing Down 

 -  Cell, 174(5), p.1041, 2018 .
<br/><br/> Just 5 years after its first demonstration as a genome editing tool, CRISPR is pretty much a household name. From its humble beginnings as a way for bacteria to chop up invading viral DNA, CRISPR has taken over our discussions of animal models, high-throughput screens, GMOs, and gene therapy-even biomedical ethics and scientific patent law-all at breakneck speed. While CRISPR is not without its drawbacks, it has major advantages in that it is programmable and applicable to countless organisms, cell types, and research questions. With over 2,500 CRISPR papers published already in 2018, it's easy to wonder whether there is anything truly new left under the sun. 
<br/><br/><label>Subjects--Topical Terms: </label><br/>ANEUPLOIDY<br/>CAS12 GENE<br/>CAS12A GENE<br/>CAS13 GENE